Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876044 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT00876044 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 88 participants.
The verdict
NCT00876044, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.
Interventions
- DRUG placebo
- DRUG aflibercept (AVE0005)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876044
The ClinicalTrials.gov registry entry for NCT00876044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00876044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876044 about?
NCT00876044 is a clinical study titled "A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients". The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters, clinical safety and pharmakokinetic (PK) parameters.
What is the current status of trial NCT00876044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2009-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00876044?
The interventions under investigation include: placebo (DRUG), aflibercept (AVE0005) (DRUG).
Who is sponsoring clinical trial NCT00876044?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.